newsfilter
← Latest News
GlobeNewswire·

Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform

  • Dr. Victor Fontenelle Bastos de Lima received the Young Researcher Award at BRAIN 2026 in Porto Alegre, Brazil, for his work evaluating Nexalin's DIFS™ 15 mA, 77.5 Hz platform.
  • The award-winning research focused on insomnia symptoms in patients with comorbid anxiety, reporting significant, durable improvements in sleep quality with large effect sizes.
  • The study was a single-center, prospective clinical trial conducted at the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo, involving 20 treatment sessions.
  • Independent scientific recognition supports Nexalin's non-invasive frequency-based neurostimulation platform as the company prepares for its product launch in Brazil.
  • Nexalin has received ANVISA approval to market, sell, & distribute its Nexalin SYNC medical device for anxiety, depression, & insomnia within Brazil.
  • The Young Researcher Award recognizes academic merit & does not constitute regulatory clearance, safety, or efficacy approval by any authority.
  • Nexalin's Gen-2 15 mA device is already approved in China, Brazil, Oman, & Israel, with the company advancing its FDA De Novo pathway for the HALO™ Clarity program.